FY2029 Earnings Forecast for PolyPid Issued By HC Wainwright

PolyPid Ltd. (NASDAQ:PYPD) – Equities researchers at HC Wainwright lowered their FY2029 earnings per share (EPS) estimates for shares of PolyPid in a research report issued on Thursday, May 14th. HC Wainwright analyst B. Folkes now anticipates that the company will earn $1.74 per share for the year, down from their prior forecast of $1.90. HC Wainwright currently has a “Buy” rating and a $13.00 price target on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($1.37) per share. HC Wainwright also issued estimates for PolyPid’s FY2030 earnings at $3.77 EPS.

A number of other equities research analysts have also recently weighed in on PYPD. Weiss Ratings cut PolyPid from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 1st. Wall Street Zen upgraded PolyPid from a “sell” rating to a “hold” rating in a research note on Saturday, March 14th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $12.25.

PolyPid Price Performance

Shares of NASDAQ PYPD opened at $4.46 on Monday. The stock has a market capitalization of $85.10 million, a P/E ratio of -2.34 and a beta of 1.41. PolyPid has a 1-year low of $2.44 and a 1-year high of $5.12. The business has a fifty day moving average price of $4.39 and a 200 day moving average price of $4.25.

PolyPid (NASDAQ:PYPD) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.12.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of PYPD. BNP Paribas Financial Markets raised its stake in shares of PolyPid by 56.1% in the third quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock worth $32,000 after purchasing an additional 3,500 shares during the last quarter. HighTower Advisors LLC purchased a new position in shares of PolyPid in the fourth quarter worth about $44,000. Jane Street Group LLC purchased a new position in shares of PolyPid in the fourth quarter worth about $66,000. Renaissance Technologies LLC purchased a new position in shares of PolyPid in the first quarter worth about $81,000. Finally, XTX Topco Ltd raised its stake in shares of PolyPid by 50.0% in the fourth quarter. XTX Topco Ltd now owns 32,661 shares of the company’s stock worth $142,000 after purchasing an additional 10,888 shares during the last quarter. 26.47% of the stock is currently owned by hedge funds and other institutional investors.

PolyPid Company Profile

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.